Literature DB >> 1971185

Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanism.

L Hedstrom1, C C Wang.   

Abstract

Inosine 5'-monophosphate dehydrogenase (IMPDH) catalyzes the oxidation of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP) with the conversion of NAD to NADH. An ordered sequential mechanism where IMP is the first substrate bound and XMP is the last product released was proposed for Tritrichomonas foetus IMPDH on the basis of product inhibition studies. Thiazole adenine dinucleotide (TAD) is an uncompetitive inhibitor versus IMP and a noncompetitive inhibitor versus NAD, which suggests that TAD binds to both E-IMP and E-XMP. Mycophenolic acid is also an uncompetitive inhibitor versus IMP and noncompetitive versus NAD. Multiple-inhibitor experiments show that TAD and mycophenolic acid are mutually exclusive with each other and with NADH. Therefore, mycophenolic acid most probably binds to the dinucleotide site of T. foetus IMPDH. The mycophenolic acid binding site was further localized to the nicotinamide subsite within the dinucleotide site: mycophenolic acid was mutually exclusive with tiazofurin, but could form ternary enzyme complexes with ADP or adenosine diphosphate ribose. NAD inhibits the IMPDH reaction at concentrations greater than 3 mM. NAD substrate inhibition is uncompetitive versus IMP, which suggests that NAD inhibits by binding to E-XMP. TAD is mutually exclusive with both NAD and NADH in multiple-inhibitor experiments, which suggests that there is one dinucleotide binding site. The ordered mechanism predicts that multiple-inhibitor experiments with XMP and TAD, mycophenolic acid, or NAD should have an interaction constant (alpha) between 0 and 1. However, alpha was greater than 1 in all cases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971185     DOI: 10.1021/bi00456a001

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Structural determinants of inhibitor selectivity in prokaryotic IMP dehydrogenases.

Authors:  Deviprasad R Gollapalli; Iain S Macpherson; George Liechti; Suresh Kumar Gorla; Joanna B Goldberg; Lizbeth Hedstrom
Journal:  Chem Biol       Date:  2010-10-29

Review 2.  IMP dehydrogenase: structure, mechanism, and inhibition.

Authors:  Lizbeth Hedstrom
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

3.  Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.

Authors:  T D Colby; K Vanderveen; M D Strickler; G D Markham; B M Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 4.  Mechanistic enzymology in drug discovery: a fresh perspective.

Authors:  Geoffrey A Holdgate; Thomas D Meek; Rachel L Grimley
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

5.  IMP dehydrogenase from Pneumocystis carinii as a potential drug target.

Authors:  M J O'Gara; C H Lee; G A Weinberg; J M Nott; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  IMP dehydrogenase from the protozoan parasite Toxoplasma gondii.

Authors:  William J Sullivan; Stacy E Dixon; Catherine Li; Boris Striepen; Sherry F Queener
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Overexpression of a cloned IMP dehydrogenase gene of Candida albicans confers resistance to the specific inhibitor mycophenolic acid.

Authors:  G A Köhler; T C White; N Agabian
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

8.  Spectroscopy and Molecular Modeling Study on the Interaction Between Mycophenolate Mofetil and Pepsin.

Authors:  Xiaoli Ma; Liuqi Guo; Qing Wang; Jiawei He; Hui Li
Journal:  J Fluoresc       Date:  2015-12-16       Impact factor: 2.217

9.  De novo GTP biosynthesis is critical for virulence of the fungal pathogen Cryptococcus neoformans.

Authors:  Carl A Morrow; Eugene Valkov; Anna Stamp; Eve W L Chow; I Russel Lee; Ania Wronski; Simon J Williams; Justine M Hill; Julianne T Djordjevic; Ulrike Kappler; Bostjan Kobe; James A Fraser
Journal:  PLoS Pathog       Date:  2012-10-11       Impact factor: 6.823

10.  Mechanistic and structural understanding of uncompetitive inhibitors of caspase-6.

Authors:  Christopher E Heise; Jeremy Murray; Katherine E Augustyn; Brandon Bravo; Preeti Chugha; Frederick Cohen; Anthony M Giannetti; Paul Gibbons; Rami N Hannoush; Brian R Hearn; Priyadarshini Jaishankar; Cuong Q Ly; Kinjalkumar Shah; Karen Stanger; Micah Steffek; Yinyan Tang; Xianrui Zhao; Joseph W Lewcock; Adam R Renslo; John Flygare; Michelle R Arkin
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.